Berenberg Bank Reiterates Entain Plc

Berenberg Bank reiterated a Buy on Entain Plc – Depositary Receipt (OTCPK:GMVHY) on November 27, 2025, with an average one‑year price target of $15.51 implying 71% upside from the $9.07 close (range $12.11–$19.91). Projected annual revenue is $5,111MM (down 1.04%) and projected non‑GAAP EPS is 1.04; institutional ownership remains small (three funds) but reported shares rose to ~1K (up 316.77%), indicating modest repositioning by funds.

Analysis

Market structure: Berenberg’s reiterated Buy and a $15.51 one‑year PT (≈+71% vs $9.07 GMVHY) re‑introduces a positive re‑rating thesis for Entain (GMVHY / LSE:ENT) but liquidity is concentrated on LSE; winners are online gambling operators with strong UK/European exposure and scalable tech; losers would be overlevered regional sportsbooks and OTC holders of ADRs who face wide spreads. Competitive dynamics: if investor flows rotate back into regulated European gaming names, Entain can regain pricing power vs smaller competitors (888, smaller operators) driven by scale in marketing and data; however global peers (Flutter FLTR.L, DraftKings DKNG) could siphon share if US expansion accelerates, so relative execution matters. Risk assessment: tail risks are regulatory shocks (UK Gambling Act tightening, US state bans) and licensing fines that could cut EBITDA by >10–30% in stressed scenarios; operational/ML failures that impair customer retention are a second tail. Time horizons: expect muted price moves in days (low OTC liquidity), potential 10–40% re-ratings within 1–6 months if buy-side rotates, and multi‑quarter fundamental impact from regulatory or M&A outcomes over 6–24 months. Trade implications: direct long via liquid LSE listing (ENT) preferable to OTC GMVHY; pair trades long ENT vs short DKNG or FLTR on valuation and US regulatory sensitivity; options plays (12–18 month call spreads) can express asymmetric upside while capping cost. Contrarian view: consensus buys rely on upside to analyst PTs without acknowledging tiny institutional U.S. ownership and OTC illiquidity—market may underprice UK regulatory tightening risk; conversely any credible M&A approach (histor precedent) would likely reprice shares quickly, so a buy is a binary risk/reward play where implied probability of takeover appears underpriced.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in Entain via the LSE ticker ENT (avoid thin OTC GMVHY execution) aiming for Berenberg PT $15.51 (~+70%) within 12 months; initial stop-loss at 20% below entry and trim 50% at +35%, exit remainder at +70% or on confirmed adverse regulatory action.
• Implement a funded pair trade: long ENT (1.5% portfolio) and short DKNG (1.0% portfolio) sized to be dollar‑neutral; rationale: ENT undervalued on UK/European cash generation vs DKNG stretched US multiple and regulatory sensitivity. Rebalance if spread moves >30% from entry.
• Use options to express upside with defined risk: buy a 12–18 month call‑spread on ENT (e.g., buy 1.0x ATM LEAP call, sell 1.5x call) sized to risk 0.5% portfolio capital; this captures re‑rating/M&A upside while limiting premium loss if regulatory risk materializes.
• Avoid establishing material positions in OTC GMVHY unless spreads tighten; for opportunistic OTC buys, limit exposure to <0.5% until 30‑day ADV improves. Monitor catalysts: UK regulator announcements, quarterly EBITDA revisions >±10%, and any confirmed M&A chatter—if any occur within 30–90 days, increase position to target size.
• If UK Gambling review proposes measures likely to reduce gross win by ≥5% or increase compliance costs >€50m annually, reduce net long exposure by at least 50% immediately and rotate into larger-cap peers with more diversified geography (FLTR.L) or into gaming suppliers with lower regulatory beta.